中国医药
中國醫藥
중국의약
CHINA MEDICINE
2013年
10期
1438-1439
,共2页
妇科再造胶囊%米非司酮%子宫肌瘤
婦科再造膠囊%米非司酮%子宮肌瘤
부과재조효낭%미비사동%자궁기류
Fukezaizao capsule%Mifepristone%Uterine fibroids
目的 观察妇科再造胶囊联合米非司酮治疗子宫肌瘤的临床效果.方法 将136例确诊为子宫肌瘤的患者完全随机分为观察组和对照组,各68例.对照组单独应用米非司酮,25 mg/d；观察组在米非司酮上的基础上加用妇科再造胶囊,6粒/次,2次/d.3个月为1个疗程,测定所有患者用药前后的孕酮、雌二醇,B型超声测量用药前后子宫及子宫肌瘤三维径线.结果 治疗后观察组和对照组患者孕酮、雌二醇水平均明显低于治疗前[观察组:(6.9±1.0) nmol/L比(19.6±3.2) nmol/L,(164±10) pmol/L比(355 ±40)pmoL/L；对照组:(9.4±2.2) nmol/L比(19.5 ± 3.2) nmol/L,(175±13) pmol/L比(324±43) pmol/L；均P＜0.05],子宫及子宫肌瘤体积均较治疗前明显缩小[观察组:(112±36)cm3比(152±46)cm3,(37±7)cm3比(60±17)cm3;对照组:(125±33)cm3比(153±44) cm3,(43±10)cm3比(58±17)cm3；均P＜0.05],且观察组治疗后孕酮、雌二醇水平及子宫体积及子宫肌瘤体积均明显低于对照组(均P＜0.05).结论 妇科再造胶囊联合米非司酮治疗子宫肌瘤较单独应用米非司酮效果更好.
目的 觀察婦科再造膠囊聯閤米非司酮治療子宮肌瘤的臨床效果.方法 將136例確診為子宮肌瘤的患者完全隨機分為觀察組和對照組,各68例.對照組單獨應用米非司酮,25 mg/d；觀察組在米非司酮上的基礎上加用婦科再造膠囊,6粒/次,2次/d.3箇月為1箇療程,測定所有患者用藥前後的孕酮、雌二醇,B型超聲測量用藥前後子宮及子宮肌瘤三維徑線.結果 治療後觀察組和對照組患者孕酮、雌二醇水平均明顯低于治療前[觀察組:(6.9±1.0) nmol/L比(19.6±3.2) nmol/L,(164±10) pmol/L比(355 ±40)pmoL/L；對照組:(9.4±2.2) nmol/L比(19.5 ± 3.2) nmol/L,(175±13) pmol/L比(324±43) pmol/L；均P＜0.05],子宮及子宮肌瘤體積均較治療前明顯縮小[觀察組:(112±36)cm3比(152±46)cm3,(37±7)cm3比(60±17)cm3;對照組:(125±33)cm3比(153±44) cm3,(43±10)cm3比(58±17)cm3；均P＜0.05],且觀察組治療後孕酮、雌二醇水平及子宮體積及子宮肌瘤體積均明顯低于對照組(均P＜0.05).結論 婦科再造膠囊聯閤米非司酮治療子宮肌瘤較單獨應用米非司酮效果更好.
목적 관찰부과재조효낭연합미비사동치료자궁기류적림상효과.방법 장136례학진위자궁기류적환자완전수궤분위관찰조화대조조,각68례.대조조단독응용미비사동,25 mg/d；관찰조재미비사동상적기출상가용부과재조효낭,6립/차,2차/d.3개월위1개료정,측정소유환자용약전후적잉동、자이순,B형초성측량용약전후자궁급자궁기류삼유경선.결과 치료후관찰조화대조조환자잉동、자이순수평균명현저우치료전[관찰조:(6.9±1.0) nmol/L비(19.6±3.2) nmol/L,(164±10) pmol/L비(355 ±40)pmoL/L；대조조:(9.4±2.2) nmol/L비(19.5 ± 3.2) nmol/L,(175±13) pmol/L비(324±43) pmol/L；균P＜0.05],자궁급자궁기류체적균교치료전명현축소[관찰조:(112±36)cm3비(152±46)cm3,(37±7)cm3비(60±17)cm3;대조조:(125±33)cm3비(153±44) cm3,(43±10)cm3비(58±17)cm3；균P＜0.05],차관찰조치료후잉동、자이순수평급자궁체적급자궁기류체적균명현저우대조조(균P＜0.05).결론 부과재조효낭연합미비사동치료자궁기류교단독응용미비사동효과경호.
Objective To observe clinical efficacy of Fukezaizao capsules combined with mifepristone in treatment of hysteromyoma.Methods All 136 cases of patients diagnosed of uterine fibroids were randomly divided into two groups.Control group was given mifepristone alonely (25 mg/d) and observation group was treated with Fukezaizao capsules (6 capsules per time,2 times per day) combined with mifepristone (25 mg/d).A course was 3 months.Progesterone and estradiol were measured in all patients before and after treatment,and the 3D diameters of the uterus and uterine fibroids were measured by B ultrasound before and after treatment.Results After treatment,the levels of progesterone and estradiol in observation group and control group were lower than those before treatment [observation group:(6.9 ± 1.0) nmol/L vs (19.6 ± 3.2) nmol/L,(164 ± 10) pmol/L vs (355 ± 40) pmol/L; control group:(9.4 ± 2.2) nmol/L vs (19.5 ± 3.2) nmol/L,(175 ± 13) pmol/L vs (324 ± 43) pmol/L; all P ＜ 0.05] ;the volumes of endometriosis and uterine fibroid were significantly reduced in observation group and control group [observation group:(112 ± 36) cm3 vs (152 ± 46) em3,(37 ± 7) cm3 vs (60 ± 17) em3 ; control group:(125 ± 33) cm3 vs (153 ± 44) cm3,(43 ± 10) cm3 vs (58 ± 17) cm3 ; all P ＜ 0.05] ; the levels of progesterone and estradiol and the volumes of endometriosis and uterine fibroid in observation group after treatment were significantly lower than those in control group (all P ＜ 0.05).Conclusion Fukezaizao capsule combination of mifepristone in treatment of hysteromyoma is better than solo mifepristone.
